T cells CD4+/CD8+ local immune modulation by prostate cancer hemi-cryoablation
Tóm tắt
Từ khóa
Tài liệu tham khảo
Reis LO, Billis A, Zequi SC, Tobias-Machado M, Viana P, Cerqueira M, Ward JF (2014) Supporting prostate cancer focal therapy: a multidisciplinary International Consensus of Experts (“ICE”). Aging Male 17(2):66–71
Sha TT, Peters M, Eldred-Evans D, Miah S, Yap T, Faure-Walker NA, Hosking-Jervis F, Thomas B, Dudderidge T, Hindley RG, McCracken S, Greene D, Nigam R, Valerio M, Minhas S, Winkler M, Arya M, Ahmed HU (2019) Early-medium-term outcomes of primary focal cryotherapy to treat nonmetastatic clinically significant prostate cancer from a prospective multicentre registry. Eur Urol. https://doi.org/10.1016/j.eururo.2018.12.030
Cerqueira MA, Laranja WW, Sanches BC et al (2015) Burden of focal cryoablation versus brachytherapy versus active surveillance in the treatment of very low-risk prostate cancer: a preliminary head-to-head comprehensive assessment. Eur J Cancer Care (Engl) 24:929–937
Reis LO, Carter HB (2015) The mind: focal cryotherapy in low-risk prostate cancer: are we treating the cancer or the mind? Int Braz J Urol 41(1):10–14
Gannon PO, Poisson AO, Delvoye N et al (2009) Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients. J Immunol Methods 348:9–17
Sanches BCF, Lalli AL, Azal Neto W, Billis A, Reis LO (2018) Are 10-, 10–12-, or > 12-mm prostate biopsy core quality control cutoffs reasonable? World J Urol 36(7):1055–1058
The nobel prize in physiology or medicine 2018. NobelPrize.org. Nobel Media AB 2018. https://www.nobelprize.org/prizes/medicine/2018/summary/ . Accessed 2 Oct 2018
Rueden CT, Eliceiri KW (2007) Visualization approaches for multidimensional biological image data. BioTechniques 43(1 Suppl):31–36
Shah TT, Kasivisvanathan V, Jameson C et al (2015) Histological outcomes after focal high-intensity focused ultrasound and cryotherapy. World J Urol 33:955–964
Soanes WA, Ablin RJ, Gonder MJ (1970) Remission of metastatic lesions following cryosurgery in prostatic cancer: immunologic considerations. J Urol 104:154–159
Di Carlo E, Magnasco S, D’Antuono T et al (2007) The prostate-associated lymphoid tissue (PALT) is linked to the expression of homing chemokines CXCL13 and CCL21. Prostate 67:1070–1080
Sabel MS (2009) Cryo-immunology: a review of the literature and proposed mechanisms for stimulatory versus suppressive immune responses. Cryobiology 58(1):1–11
Garcia-Hernnández ML, Uribe-Uribe NO, Espinosa-González R, Kast WM, Khader SA, Rangel-Moreno J (2017) A unique cellular and molecular microenvironment is present in tertiary lymphoid organs of patients with spontaneous prostate cancer regression. Front Immunol 17(8):563
Davidsson S, Ohlson A, Andersson S et al (2013) CD4 helper T cells, CD8 cytotoxic T cells, and FOXP3þ regulatory T cells with respect to lethal prostate cancer. Mod Pathol 26:448–455
Becht E, Giraldo NA, Germain C et al (2016) Immune contexture, immunoscore, and malignant cell molecular subgroups for prognostic and theranostic classifications of cancers. Adv Immunol 130:96–190
Tucker JA, Jochems C, Gulley JL, Schlom J, Tsang KY (2012) Immunotherapy: shifting the balance of cell-mediated immunity and suppression in human prostate cancer. Cancers (Basel) 4(4):1333–1348
Waitz R, Solomon SB, Petre EN et al (2012) Potent induction of tumor immunity by combining tumor cryoablation with anti-CTLA-4 therapy. Cancer Res 72(2):430–439
Davidsson S, Andren O, Ohlson AL, Carlsson J, Andersson SO, Giunchi F, Rider JR, Fiorentino M (2018) FOXP3+ regulatory T cells in normal prostate tissue, post-atrophic hyperplasia, prostatic intraepithelial neoplasia, and tumor histological lesions in men with and without prostate cancer. Prostate 78(1):40–47
McArdle PA, Canna K, Mcmillan DC, Underwood MA et al (2004) The relationship between T-lymphocyte subset infiltration and survival in patients with prostate cancer. Br J Cancer 91:541–543
Sharabi AB, Nirschl CJ, Kochel CM (2015) Stereotactic radiation therapy augments antigen-specific PD-1-mediated anti-tumor immune responses via cross-presentation of tumor antigen. Cancer Immunol Res 3:345–355
Waitz R, Solomon SB, Petre EN, Trumble AE, Fasso M, Norton L et al (2012) Potent induction of tumor immunity by combining tumor cryoablation with anti-CTLA-4 therapy. Cancer Res 72:430–439
Benzon B, Glavaris SA, Simons BW, Hughes RM, Ghabili K, Mullane P, Miller R, Nugent K, Shinder B, Tosoian J, Fuchs EJ, Tran PT, Hurley PJ, Vuica-Ross M, Schaeffer EM, Drake CG, Ross AE (2018) Combining immune check-point blockade and cryoablation in an immunocompetent hormone sensitive murine model of prostate cancer. Prostate Cancer Prostatic Dis 21(1):126–136
ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US) (2015) Identifier NCT02423928, Phase I Clinical Trial of Cryoimmunotherapy Against Prostate Cancer (CryoIT). https://clinicaltrials.gov/ct2/show/study/NCT02423928 . Accessed 26 May 2019
Yang ZR, Zhao N, Meng J, Shi ZL, Li BX, Wu XW, Li P, Zhang Q, Wei XB, Fu S (2016) Peripheral lymphocyte subset variation predicts prostate cancer carbon ion radiotherapy outcomes. Oncotarget 7(18):26422–26435